DACS
TRVI icon

Dymon Asia Capital (Singapore)’s Trevi Therapeutics TRVI Stock Holding History

Dymon Asia Capital (Singapore)’s Portfolio TRVI Stock Details TRVI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$658K Buy
+35,300
New +$513K 0.03% 186
2026
Q1 		– Sell
-20,000
Closed -$250K – 321
2025
Q4 		$250K Buy
+20,000
New +$231K 0.02% 217

Other funds holding TRVI

Pictet Asset Management
Pictet Asset Management Carouge, Switzerland $105B AUM 38.07% 1-Year Est. Return
Assenagon Asset Management
Assenagon Asset Management Senningerberg, Luxembourg $80.2B AUM 50.57% 1-Year Est. Return
NFT
Nan Fung Trinity Central, Hong Kong, Hong Kong $1.01B AUM 64.38% 1-Year Est. Return
PCM
Peregrine Capital Management Minneapolis, Minnesota $3.08B AUM 29.51% 1-Year Est. Return
TCOT
Trust Company of Toledo Holland, Ohio $1.2B AUM 33.38% 1-Year Est. Return
EAM
Erste Asset Management Vienna, Austria $12.9B AUM 52.69% 1-Year Est. Return
PP
PFS Partners Mine Hill, New Jersey $247M AUM 29.02% 1-Year Est. Return
ZCP
Z3 Capital Partners Richmond, Virginia $476M AUM
HCA
Harbour Capital Advisors Tysons Corner, Virginia $549M AUM 54.99% 1-Year Est. Return
New York State Common Retirement Fund
New York State Common Retirement Fund Albany, New York $79.3B AUM 43.63% 1-Year Est. Return

Dymon Asia Capital (Singapore)'s TRVI Position: Q2 2026 in Review

Dymon Asia Capital (Singapore) opened a new position in Trevi Therapeutics (TRVI) in Q2 2026: 35,300 shares worth $658K. The stake represents 0.03% of the portfolio and ranks #186 among its holdings. This is a return to the name: Dymon Asia Capital (Singapore) previously reported a position in TRVI as recently as Q4 2025.

Dymon Asia Capital (Singapore) first reported a position in TRVI in Q4 2025 and has held it in 2 quarters since. 35 funds tracked by Wall St. Rank hold TRVI as of Q2 2026.

  • Dymon Asia Capital (Singapore) held 35,300 shares of Trevi Therapeutics worth $658K as of Q2 2026.
  • Trevi Therapeutics was a new Dymon Asia Capital (Singapore) position in Q2 2026.
  • Trevi Therapeutics made up 0.03% of Dymon Asia Capital (Singapore)'s portfolio in Q2 2026, its #186 holding.
  • Dymon Asia Capital (Singapore) first reported a position in Trevi Therapeutics in Q4 2025 and has held it in 2 quarters since.
  • 35 funds tracked by Wall St. Rank held Trevi Therapeutics as of Q2 2026.

Based on Dymon Asia Capital (Singapore)'s 13F filing for Q2 2026, filed 23 Jul 2026.